Identification of miRNAs correlating with stage and progression of colorectal cancer

IF 2.7 Q3 ONCOLOGY

Colorectal Cancer Pub Date : 2019-11-01 DOI:10.2217/crc-2018-0014

M. Asadi, Shoan Taheri Talesh, M. Gjerstorff, D. Shanehbandi, B. Baradaran, S. Hashemzadeh, V. Zafari

引用次数: 13

Abstract

Aim: miRNAs control biological processes that are implicated in carcinogenesis, and have been researched as potential biomarkers for colorectal cancer (CRC). The aim of the current study was to evaluate the miRNA expression profile in CRC patients to determine their potential to be used as biomarkers in the disease. Materials & methods: Total 47 tissues and their matched marginal tissues, as control group, were obtained from CRC patients. The transcript levels of a selected panel of 15 cancer-associated miRNAs were quantified via real-time gene expression method. Results: miR-155, miR130a, miR-181b, miR-196a, miR-200c and miR-224 were significantly upregulated, while miR122, miR-132, miR-203b, miR330, miR-323, miR-378a-3p and miR-598 we significantly downregulated in CRC. Conclusion: We identified a panel of miRNAs that may be involved in the etiology and pathogenesis of CRC, and may be used for novel diagnostic and therapeutic strategies.

查看原文本刊更多论文

与癌症分期和进展相关的miRNA的鉴定

目的:mirna控制与癌变有关的生物过程，并已被研究为结直肠癌(CRC)的潜在生物标志物。本研究的目的是评估CRC患者的miRNA表达谱，以确定其作为该疾病生物标志物的潜力。材料与方法:选取结直肠癌患者47个组织及其匹配的边缘组织作为对照组。通过实时基因表达法，对选定的15种癌症相关mirna的转录水平进行了量化。结果:miR-155、miR130a、miR-181b、miR-196a、miR-200c和miR-224在结直肠癌中显著上调，mir - 122、miR-132、miR-203b、miR330、miR-323、miR-378a-3p和miR-598在结直肠癌中显著下调。结论:我们发现了一组可能与结直肠癌的病因和发病机制有关的mirna，并可能用于新的诊断和治疗策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Colorectal Cancer ONCOLOGY-

自引率

0.00%

发文量

期刊介绍： Colorectal cancer is a major cause of morbidity and mortality, particularly in the developed world. Risk factors for colorectal cancer are on the rise in many countries; populations are aging, and obesity and diabetes are increasing. National screening programs are helping to detect cancer while it is still curable; however, colorectal cancer remains the third leading cause of cancer deaths in the USA and options are still limited for those with more advanced disease. Consequently, colorectal cancer is a major research priority for government, pharmaceutical companies and non-profit organizations. Research into diagnosis and optimum treatment of the disease is progressing rapidly, with new advances reported every day. Colorectal Cancer presents reviews, analysis and commentary. on all aspects of colorectal cancer.